Constellation Brands, Inc. (STZ) Reaches $197.51 High on Jul, 17; Artal Group Sa Upped Atara Biotherapeutics (ATRA) Position By $3.85 Million

July 17, 2017 - By Maria Brooks

The stock of Constellation Brands, Inc. (NYSE:STZ) reached all time high today, Jul, 17 and still has $203.44 target or 3.00% above today’s $197.51 share price. This indicates more upside for the $38.98 billion company. This technical setup was reported by If the $203.44 PT is reached, the company will be worth $1.17 billion more. About 1.21 million shares traded. Constellation Brands, Inc. (NYSE:STZ) has risen 17.20% since July 17, 2016 and is uptrending. It has outperformed by 0.50% the S&P500.

Artal Group Sa increased Atara Biotherapeutics Inc (ATRA) stake by 122.22% reported in 2016Q4 SEC filing. Artal Group Sa acquired 275,000 shares as Atara Biotherapeutics Inc (ATRA)’s stock declined 2.88%. The Artal Group Sa holds 500,000 shares with $7.10M value, up from 225,000 last quarter. Atara Biotherapeutics Inc now has $471.90 million valuation. The stock rose 6.64% or $1 reaching $16.05 per share. About 188,781 shares traded. Atara Biotherapeutics Inc (NASDAQ:ATRA) has declined 7.28% since July 17, 2016 and is downtrending. It has underperformed by 23.98% the S&P500.

Investors sentiment increased to 1.86 in Q4 2016. Its up 0.38, from 1.48 in 2016Q3. It improved, as 5 investors sold ATRA shares while 17 reduced holdings. 11 funds opened positions while 30 raised stakes. 22.89 million shares or 2.84% more from 22.25 million shares in 2016Q3 were reported. 12 West Capital Mgmt LP holds 1.01% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 398,700 shares. Ubs Asset Mgmt Americas Incorporated has invested 0.01% in Atara Biotherapeutics Inc (NASDAQ:ATRA). Blackrock Ltd Limited Liability Company stated it has 11,615 shares or 0% of all its holdings. 47,904 were accumulated by California State Teachers Retirement Systems. Alps accumulated 0% or 27,736 shares. Royal National Bank & Trust Of Canada stated it has 0% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA). Savings Bank Of Ny Mellon Corporation reported 0% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA). Massachusetts-based Baupost Ltd Ma has invested 0.99% in Atara Biotherapeutics Inc (NASDAQ:ATRA). The Kansas-based Creative Planning has invested 0% in Atara Biotherapeutics Inc (NASDAQ:ATRA). Parametric Llc invested 0% in Atara Biotherapeutics Inc (NASDAQ:ATRA). 5,994 are owned by Blackrock Group Inc Limited. Credit Suisse Ag holds 0% or 38,350 shares. Eagle Asset Mgmt Inc invested in 0.1% or 1.11M shares. Proshare Limited Co reported 22,796 shares. Franklin Street Nc has invested 0.03% in Atara Biotherapeutics Inc (NASDAQ:ATRA).

Among 6 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 4 have Buy rating, 2 Sell and 0 Hold. Therefore 67% are positive. Atara Biotherapeutics had 14 analyst reports since September 9, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Wednesday, November 18 by Goldman Sachs. As per Friday, October 9, the company rating was initiated by William Blair. The rating was downgraded by Citigroup on Tuesday, December 15 to “Sell”. The rating was initiated by JMP Securities on Friday, September 25 with “Mkt Perform”. JMP Securities maintained the stock with “Market Outperform” rating in Tuesday, December 15 report. The firm has “Buy” rating by Jefferies given on Monday, October 24. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, March 9 report. Citigroup maintained the shares of ATRA in report on Friday, August 19 with “Sell” rating. The firm earned “Sell” rating on Monday, August 22 by Citigroup. The firm earned “Sell” rating on Thursday, September 15 by Goldman Sachs.

Artal Group Sa decreased Avexis Inc stake by 50,000 shares to 150,000 valued at $7.16M in 2016Q4. It also reduced Chemocentryx Inc (NASDAQ:CCXI) stake by 653,722 shares and now owns 546,278 shares. Acceleron Pharma Inc (NASDAQ:XLRN) was reduced too.

Since February 2, 2017, it had 0 buys, and 26 selling transactions for $3.86 million activity. $13,150 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) was sold by Gallagher Carol Giltner on Thursday, June 8. The insider Haqq Christopher sold $216,054. Another trade for 4,000 shares valued at $60,440 was made by MCGRATH JOHN on Monday, May 15. 4,800 shares valued at $65,568 were sold by Ciechanover Isaac E. on Thursday, February 2. On Thursday, February 9 the insider Turner Heather D sold $192,067. 2,500 Atara Biotherapeutics Inc (NASDAQ:ATRA) shares with value of $50,000 were sold by Soffer Gad. Clark Mitchall G. sold 3,873 shares worth $59,063.

Among 20 analysts covering Constellation Brands (NYSE:STZ), 14 have Buy rating, 0 Sell and 6 Hold. Therefore 70% are positive. Constellation Brands has $280 highest and $130 lowest target. $192.16’s average target is -2.71% below currents $197.51 stock price. Constellation Brands had 53 analyst reports since August 27, 2015 according to SRatingsIntel. HSBC upgraded Constellation Brands, Inc. (NYSE:STZ) on Wednesday, February 1 to “Hold” rating. Barclays Capital maintained Constellation Brands, Inc. (NYSE:STZ) on Thursday, April 7 with “Overweight” rating. On Wednesday, September 16 the stock rating was maintained by FinnCap with “Corporate”. SunTrust maintained Constellation Brands, Inc. (NYSE:STZ) on Thursday, October 6 with “Buy” rating. The stock of Constellation Brands, Inc. (NYSE:STZ) has “Outperform” rating given on Tuesday, April 11 by Cowen & Co. Morgan Stanley maintained Constellation Brands, Inc. (NYSE:STZ) on Thursday, October 6 with “Overweight” rating. The company was maintained on Thursday, October 8 by RBC Capital Markets. The stock of Constellation Brands, Inc. (NYSE:STZ) earned “Buy” rating by Stifel Nicolaus on Thursday, August 27. Stifel Nicolaus maintained the stock with “Buy” rating in Friday, June 30 report. The rating was maintained by Goldman Sachs with “Buy” on Friday, June 30.

Investors sentiment is 0.98 in Q4 2016. Its the same as in 2016Q3. It is flat, as 74 investors sold Constellation Brands, Inc. shares while 244 reduced holdings. only 93 funds opened positions while 219 raised stakes. 144.26 million shares or 0.98% less from 145.68 million shares in 2016Q3 were reported. Us Financial Bank De accumulated 0.02% or 42,338 shares. Montecito Bancorporation & Tru stated it has 1,255 shares. Wealthtrust Axiom Limited holds 0.14% or 2,500 shares. Symphony Asset Management invested in 0.25% or 15,627 shares. American Registered Investment Advisor Inc invested in 0.46% or 6,550 shares. Jnba reported 0% of its portfolio in Constellation Brands, Inc. (NYSE:STZ). Da Davidson accumulated 0.02% or 5,303 shares. 75,787 are held by Lombard Odier Asset Mgmt (Usa). Fisher Asset Limited Co owns 1,347 shares for 0% of their portfolio. Kensico Cap Corp reported 15.51% in Constellation Brands, Inc. (NYSE:STZ). Strs Ohio accumulated 397,948 shares. Scott And Selber invested in 2.23% or 22,630 shares. Monetary Mngmt Grp invested in 0.04% or 600 shares. The New York-based Gotham Asset Mgmt Ltd Com has invested 0.11% in Constellation Brands, Inc. (NYSE:STZ). Webster Commercial Bank N A invested in 7,329 shares or 0.16% of the stock.

Analysts await Constellation Brands, Inc. (NYSE:STZ) to report earnings on October, 4. They expect $2.16 earnings per share, up 22.03% or $0.39 from last year’s $1.77 per share. STZ’s profit will be $426.29M for 22.86 P/E if the $2.16 EPS becomes a reality. After $2.34 actual earnings per share reported by Constellation Brands, Inc. for the previous quarter, Wall Street now forecasts -7.69% negative EPS growth.

Constellation Brands, Inc. is an international beverage alcohol company. The company has market cap of $38.98 billion. The Firm is a producer and marketer of beer, wine and spirits with activities in the United States, Canada, Mexico, New Zealand and Italy. It has a 26.27 P/E ratio. The Company’s divisions include Beer, Wine and Spirits, and Corporate Operations and Other.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: